The New England Journal of Medicine JANUARY 25, 2018

Brentuximab Vedotin with Chemotherapy for Stage III or IV Classical Hodgkin Lymphoma (ECHELON-1)

Joseph M. Connors, et al.

Bottom Line

The ECHELON-1 trial demonstrated that substituting bleomycin with brentuximab vedotin in standard frontline chemotherapy (A+AVD vs. ABVD) provides a durable improvement in both progression-free survival and overall survival for patients with advanced-stage classical Hodgkin lymphoma.

Key Findings

1. At the primary analysis (median follow-up 24.6 months), A+AVD significantly improved modified progression-free survival (mPFS) per independent review, with a hazard ratio of 0.77 (95% CI 0.60-0.98; P=0.035).

2. Long-term analysis at a median follow-up of 73 months demonstrated superior overall survival (OS) for A+AVD, with a 6-year OS rate of 93.9% versus 89.4% in the ABVD group (HR 0.59; 95% CI 0.40-0.88; P=0.009).

3. The 7-year progression-free survival rates remained higher with A+AVD at 82.3% compared to 74.5% with ABVD (HR 0.68; 95% CI 0.53-0.86).

4. While A+AVD was associated with higher rates of peripheral neuropathy and febrile neutropenia, the safety profile was considered manageable with the use of prophylactic growth factors and dose modifications.

Study Design

Design

RCT

Open-Label

Sample

1,334

Patients

Duration

73 mo

Median

Setting

Multicenter, Global

Population Patients aged 18 years or older with previously untreated Stage III or IV classical Hodgkin lymphoma

Intervention Brentuximab vedotin (1.2 mg/kg) plus doxorubicin, vinblastine, and dacarbazine (A+AVD)

Comparator Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)

Outcome Modified progression-free survival (mPFS) defined as the time to progression, death, or receipt of additional anticancer therapy for patients who are not in complete response after completion of frontline therapy

Study Limitations

• The study was open-label, which may introduce bias in investigator-assessed outcomes and reporting of toxicity.

• The trial was not powered for subgroup analyses, specifically regarding age or specific disease risk factor categories, necessitating caution in interpreting those specific results.

• While peripheral neuropathy occurred more frequently in the experimental arm, long-term monitoring for resolution was required, highlighting a potential quality-of-life consideration compared to the standard ABVD regimen.

Clinical Significance

ECHELON-1 established A+AVD as a superior frontline standard of care for advanced-stage classical Hodgkin lymphoma by demonstrating both a primary progression-free survival benefit and, notably, a statistically significant improvement in overall survival, a rare achievement in first-line trials for this disease.

Historical Context

For decades, ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) served as the gold standard for frontline Hodgkin lymphoma. The ECHELON-1 trial sought to improve outcomes and reduce bleomycin-associated pulmonary toxicity by integrating the CD30-directed antibody-drug conjugate brentuximab vedotin into the chemotherapy backbone.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Brentuximab vedotin is an antibody-drug conjugate (ADC) used in the ECHELON-1 trial. What is the specific cellular target of the antibody component, and why was bleomycin omitted from the experimental A+AVD arm?

Key Response

Brentuximab vedotin targets CD30, which is characteristically expressed on Reed-Sternberg cells in classical Hodgkin lymphoma. Bleomycin was omitted from the experimental arm (A+AVD) because the combination of brentuximab vedotin and bleomycin was found to cause an unacceptably high rate of pulmonary toxicity during Phase I trials.

Resident

When deciding between A+AVD and ABVD for a patient with advanced-stage Hodgkin lymphoma, what are the primary differences in toxicity profiles that should guide your clinical counseling?

Key Response

A+AVD is associated with a significantly higher risk of peripheral neuropathy and febrile neutropenia; the latter requires mandatory primary prophylaxis with G-CSF. Conversely, ABVD carries the risk of bleomycin-induced lung injury (BILI), which can be fatal. Clinicians should favor A+AVD in patients with pre-existing pulmonary disease or those who wish to avoid the risk of lung toxicity, while monitoring closely for neuropathic symptoms.

Fellow

The ECHELON-1 trial demonstrated an overall survival (OS) benefit at the 6-year mark. How does this finding influence the debate between starting with a more intensive frontline regimen (A+AVD) versus a PET-adapted strategy like the one used in the RATHL trial?

Key Response

The RATHL trial sought to reduce toxicity by dropping bleomycin in PET2-negative patients, but it was not powered for OS. ECHELON-1's demonstrated 4.5% absolute OS benefit (93.9% vs 89.4%) suggests that maximizing frontline therapy with A+AVD may be superior to 'de-escalation' strategies, even though the latter may reduce toxicity for a subset of patients.

Attending

In the context of the ECHELON-1 OS data, how do you interpret the clinical significance of 'modified progression-free survival' (mPFS) used as the initial primary endpoint, and how has this impacted your long-term management of Stage IV HL patients?

Key Response

mPFS included the use of subsequent anticancer therapy as an event, which was controversial because it didn't always reflect disease progression. However, the eventual OS benefit validated that A+AVD provides a deeper, more durable remission. For Stage IV patients, who traditionally have poorer outcomes, the OS data makes A+AVD a preferred standard, provided the patient can tolerate G-CSF and the risk of reversible neuropathy.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Critique the use of a fixed-duration control arm in ECHELON-1. How might the inclusion of a PET-adapted de-escalation arm (as seen in the RATHL trial) have altered the Hazard Ratio for Progression-Free Survival (PFS)?

Key Response

The control arm (ABVD) was given for 6 cycles regardless of PET results. If a PET-adapted arm had been used (de-escalating to AVD for PET2-negative patients), the control arm's toxicity might have decreased without necessarily compromising efficacy, potentially narrowing the safety gap but also highlighting the A+AVD arm's superior efficacy. A de-escalated control arm would have provided a more 'modern' comparator for international standard-of-care.

Journal Editor

As a reviewer, evaluate the potential for 'lead-time' or 'ascertainment' bias regarding the modified PFS endpoint in ECHELON-1, and discuss whether the 6-year OS data successfully mitigates these concerns.

Key Response

Modified PFS was criticized because 'subsequent therapy' is a subjective clinician decision, not a hard radiographic event. This could lead to overestimating progression in the control arm. However, the 6-year OS data is the 'gold standard' endpoint and is not subject to the same interpretation bias; its statistical significance (p=0.009) confirms the regimen's clinical superiority and justifies the high-impact status of the study.

Guideline Committee

Does the 6-year follow-up of ECHELON-1 warrant a change in the Level of Evidence for A+AVD in Stage III/IV disease, and how does it compare to current NCCN recommendations regarding escalated BEACOPP?

Key Response

The ECHELON-1 OS data solidifies A+AVD as a Category 1, preferred recommendation for advanced-stage HL. While escalated BEACOPP (used primarily in Europe) also offers high efficacy, it carries higher risks of secondary malignancies and infertility. NCCN guidelines now favor A+AVD over ABVD for its superior OS, and often over BEACOPP for its more favorable long-term safety profile regarding myelodysplasia and fertility.

Clinical Landscape

Noteworthy Related Trials

2009

HD14 Trial

n = 1527 · JCO

Tested

BEACOPPesc chemotherapy

Population

Patients with early-stage unfavorable Hodgkin lymphoma

Comparator

ABVD

Endpoint

Progression-free survival

Key result: BEACOPPesc improved progression-free survival compared to ABVD, albeit with higher toxicity profiles.

2010

HD10 Trial

n = 1370 · NEJM

Tested

ABVD chemotherapy (2 cycles) plus involved-field radiotherapy

Population

Patients with early-stage favorable Hodgkin lymphoma

Comparator

ABVD (4 cycles) or BEACOPPesc (2 cycles) plus radiotherapy

Endpoint

Progression-free survival

Key result: Two cycles of ABVD followed by 20 Gy of involved-field radiotherapy provided excellent tumor control with minimal toxicity.

2015

AETHERA Trial

n = 329 · Lancet

Tested

Brentuximab vedotin consolidation

Population

Patients at high risk of relapse after autologous stem-cell transplantation

Comparator

Placebo

Endpoint

Progression-free survival

Key result: Brentuximab vedotin significantly improved progression-free survival in patients at high risk of relapse.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis